• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Alogliptin benzoate for the treatment of type 2 diabetes.
【24h】

Alogliptin benzoate for the treatment of type 2 diabetes.

机译：阿格列汀苯甲酸酯用于治疗2型糖尿病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Alogliptin is a highly selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). It is one of several agents of this class now available for treatment of type 2 diabetes. AREAS COVERED: This review is based upon a PubMed search and personal experience with alogliptin. The pharmacokinetics and pharmacodynamics of alogliptin are reviewed. The glucose-lowering effect of this agent is discussed as monotherapy and in combination with metformin, sulfonylurea, piogilitazone and insulin. The potential adverse effects of alogliptin are summarized. Alogliptin is compared with the other available DPP-4 inhibitors. EXPERT OPINION: Alogliptin is an additional choice in the group of DPP-4 inhibitors. As a group, these agents have a relatively modest glucose-lowering effect, inferior to that of metformin, sulfonylureas, and insulin. They do not have the benefit of weight loss offered by the glucagon-like polypeptide (GLP)-1 agonists. The primary use of DPP-4 inhibitors is in combination with other hypoglycemic agents, mainly metformin. Their principal advantage is a low incidence of hypoglycemia, making these agents desirable in patients such as the elderly and those with cardiac disease. A greater use of alogliptin and other DPP-4 inhibitors will occur if long-term studies show reduced cardiac events or long-term retention of insulin secretory capacity. The Examine Trial, a large study of alogliptin in coronary disease patients, is now underway and could provide important supportive data.
机译：简介：阿格列汀是二肽基肽酶-4（DPP-4）酶的高度选择性抑制剂。它是目前可用于治疗2型糖尿病的此类药物之一。涵盖区域：这篇评论是基于PubMed搜索和对alogliptin的个人经验得出的。综述了阿格列汀的药代动力学和药效学。这种药物的降糖作用已作为单一疗法进行了讨论，并与二甲双胍，磺酰脲，吡格列酮和胰岛素联合使用。总结了阿格列汀的潜在不良反应。将阿格列汀与其他可用的DPP-4抑制剂进行了比较。专家意见：阿格列汀是DPP-4抑制剂组中的另一选择。作为一组，这些药物具有相对适度的降糖作用，不如二甲双胍，磺酰脲和胰岛素。它们没有胰高血糖素样多肽（GLP）-1激动剂提供的减肥效果。 DPP-4抑制剂的主要用途是与其他降糖药（主要是二甲双胍）合用。它们的主要优点是低血糖的发生率低，使这些药物成为老年人和心脏病患者的理想选择。如果长期研究显示心脏事件减少或胰岛素分泌能力长期保留，则将大量使用阿格列汀和其他DPP-4抑制剂。正在进行的一项关于冠状动脉疾病患者中大剂量阿格列汀的研究试验试验正在进行中，该试验可以提供重要的支持性数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号